Refine by
Cannabinoid Receptor Manufacturer
7 companies found
Manufacturerbased inBerwyn, PENNSYLVANIA (USA)
Virpax Pharmaceuticals specializes in developing novel and proprietary drug-delivery systems across various pain and CNS disorder indications to enhance compliance and to optimize the efficacy of each product candidate. Our transforming ...
Benefits: NobrXiol may be using significantly less pharmaceutical-grade CBD than current FDA approved oral CBD dosing. NobrXiol may achieve higher efficiency via the nasal route and reduce peripheral side effects like dose dumping due to high-fat ...
Manufacturerbased inSantiago de Compostela, SPAIN
We develop and commercialize new chemical tools to spread the use of fluorescence-based methods in drug discovery. Celtarys is a newly created company focused on the development of innovative chemical tools that improve the efficiency of the High ...
Our potent hCB cannabinoids receptors fluorescent ligand shows high affinity for hCB1/CB2 cannabinoids receptor (Ki =44.8 nM and 7.4 nM , respectively in radioligand binding assay). ...
Manufacturerbased inThines (Nivelles), BELGIUM
Trenker Pharmaceutical Laboratories was founded in 1933 by Rodolphe Henri Trenker with the aim of producing and distributing high quality pharmaceutical products, food supplements and medical devices that comply with the strictest European ...
Manufacturerbased inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Tropisetron Hydrochloride (SDZ-ICS-930) is an effective neuroprotective agent that acts as a 5-HT3 receptor antagonist, a calmodulin inhibitor, and an α7-nAChRreceptor agonist, with an IC50 of 70.1 nM for the 5-HT3 receptor. Tropisetron ...
Manufacturerbased inNew York, NEW YORK (USA)
We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we seek to capitalize on ...
We are developing MRI-1867, our licensed rationally designed, orally available, dual-action, hybrid, small molecule that is an inverse agonist of the CB1 receptor, as well as an inhibitor of the iNOS ...
Manufacturerbased inMontreal, QUEBEC (CANADA)
As a specialty therapeutics, clinical-stage biotech company, Inversago Pharma develops new generations of peripherally-acting cannabinoid-1 receptor (CB1) inverse agonists for the treatment of diabetic kidney disease, type 1 and type 2 diabetes, ...
CB1 Receptors: Signaling the Brain from the Periphery: The endocannabinoid system is responsible for both homeostasis and equilibrium of the human metabolism. It is involved in regulating several pathways linked to energy intake, ...
Manufacturerbased inVancouver, BRITISH COLUMBIA (CANADA)
InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet ...